Celgene Corporation
Investor Relations Department
86 Morris Avenue
Summit, NJ 07901
United States

Visit IR website
Sign-up for e-mail alerts

NASDAQ: CELG	
Last Trade:	123.75
Trade Time:	11:34 AM ET Mar 24, 2017
Change:	0.53 (0.430%)
Day Range	123.30 - 123.96
52-Week Range	94.42 - 127.64
Volume	840,615

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID®, VIDAZA®, THALOMID®, POMALYST®/IMNOVID®, ABRAXANE®, OTEZLA® and ISTODAX®. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These candidates include our IMiDs... (more)

Stock Performance

Press Releases [View all]

Mar 5, 2017
Oral OTEZLA® (Apremilast) Demonstrated Significant Improvement versus Placebo in Trial of Patients with Moderate Plaque Psoriasis Who Were Naïve to Systemic and Biologic Therapy

Mar 3, 2017
Celgene to Present New Data from Clinical Trials on Oral OTEZLA® (apremilast) at American Academy of Dermatology Congress

Mar 1, 2017
FDA Accepts New Drug Application and Grants Priority Review for Enasidenib in Relapsed or Refractory AML with an IDH2 Mutation

Feb 27, 2017
Celgene Corporation to Webcast at Upcoming Investor Conferences

Feb 24, 2017
REVLIMID® (Lenalidomide) Approved by the European Commission as Monotherapy for the Maintenance Treatment of Patients with Newly Diagnosed Multiple Myeloma after Autologous Stem Cell Transplantation

Financials [View all]

Feb 10, 2017
Annual Report (10-K)

Apr 28, 2016
Proxy Statement (DEF 14A)

Oct 27, 2016
Quarterly Report (10-Q)

Jul 28, 2016
Quarterly Report (10-Q)

May 3, 2016
Quarterly Report (10-Q)